4-phenoxybutan-2-yl 4-methylbenzenesulfonate | 116871-23-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-phenoxybutan-2-yl 4-methylbenzenesulfonate
• 英文别名: 4-phenoxy-2-butyl tosylate
• CAS: 116871-23-9
• 化学式: C₁₇H₂₀O₄S
• 分子量: 320.409
• InChiKey: WVQWPOYKBIGQKC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  22
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  61
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-phenoxybutan-2-yl 4-methylbenzenesulfonate 、 二乙胺 生成 1-methyl-3-phenoxypropyldiethylamine
  参考文献：
  名称：

  IBUKI, TADAYUKI;SUGIHARA, TAISUKE;KAWAKUBO, HIROMU;SONE, TAKANORI

  摘要：

  DOI：
• 作为产物：
  描述：

  3-phenoxypropionaldehyde 在 三甲胺盐酸盐 、 三乙胺 作用下， 以 乙醚 、 二氯甲烷 为溶剂， 反应 2.0h， 生成 4-phenoxybutan-2-yl 4-methylbenzenesulfonate
  参考文献：
  名称：

  低压下未活化仲烷基甲苯磺酸盐的钴催化甲硅烷基羰基化

  摘要：

  据报道由未活化的仲烷基甲苯磺酸酯催化制备甲硅烷基烯醇醚。在温和的条件下，在一氧化碳的低压下使用便宜的钴催化剂。亲核性的阴离子羰基钴促进了一系列烷基甲苯磺酸盐的催化活化。甲硅烷基羰基化为从简单的起始原料合成有价值的甲硅烷基烯醇醚提供了一种实用的方法。

  DOI：

  10.1021/acs.orglett.7b02117

文献信息

• 3-Aminoindazole derivatives
  申请人：Asahi, Kasei, Kogyo, Kabushiki, Kaisha

  公开号：US04474964A1

  公开（公告）日：1984-10-02

  A compound of the formula (I): ##STR1## wherein W.sub.1 is a hydrogen atom or a ##STR2## group wherein Y is a C.sub.1-6 alkylene group or a C.sub.1-6 alkylene group having a C.sub.1-6 alkyl group substituent; and R.sub.1 and R.sub.2 each independently is a hydrogen atom or a C.sub.1-6 alkyl group and R.sub.1 and R.sub.2 may form a C.sub.4-6 heterocyclic ring or a nitrogen-containing C.sub.4-6 heterocyclic ring together with the adjacent nitrogen atom and the C.sub.4-6 heterocyclic rings may have at least one C.sub.1-6 alkyl group, hydroxyl group or halogen atom; W.sub.2 is a hydrogen atom or a ##STR3## group wherein Z is a C.sub.1-6 alkylene group or a C.sub.1-6 alkylene group having a C.sub.1-6 alkyl group substituent; and R.sub.3 and R.sub.4 each independently is a hydrogen atom or a C.sub.1-6 alkyl group and R.sub.3 and R.sub.4 may form a C.sub.4-6 heterocyclic ring or a nitrogen-containing C.sub.4-6 heterocyclic ring together with the adjacent nitrogen atom and the C.sub.4-6 heterocyclic rings may have at least one C.sub.1-6 alkyl group, hydroxyl group or halogen atom; when W.sub.1 is a hydrogen atom, W.sub.2 is the ##STR4## group; and when W.sub.2 is a hydrogen atom, W.sub.1 is the ##STR5## group; and the pharmaceutically acceptable acid addition salt thereof having antiinflammatory, analgesic and digestive tract ulcer suppressing activity.

  该化合物的结构式为：##STR1##其中W.sub.1是氢原子或##STR2##基团，其中Y是C.sub.1-6烷基烯基或具有C.sub.1-6烷基烯基取代基的C.sub.1-6烷基烯基；R.sub.1和R.sub.2各自独立地是氢原子或C.sub.1-6烷基基团，且R.sub.1和R.sub.2可以与相邻氮原子一起形成C.sub.4-6杂环环或含氮C.sub.4-6杂环环，且C.sub.4-6杂环环可能至少有一个C.sub.1-6烷基基团、羟基或卤原子；W.sub.2是氢原子或##STR3##基团，其中Z是C.sub.1-6烷基烯基或具有C.sub.1-6烷基烯基取代基的C.sub.1-6烷基烯基；R.sub.3和R.sub.4各自独立地是氢原子或C.sub.1-6烷基基团，且R.sub.3和R.sub.4可以与相邻氮原子一起形成C.sub.4-6杂环环或含氮C.sub.4-6杂环环，且C.sub.4-6杂环环可能至少有一个C.sub.1-6烷基基团、羟基或卤原子；当W.sub.1是氢原子时，W.sub.2是##STR4##基团；当W.sub.2是氢原子时，W.sub.1是##STR5##基团；及其具有抗炎、镇痛和抑制消化道溃疡活性的药用酸盐。
• Indazole derivatives
  申请人：Asahi Kasei Kogyo Kabushiki Kaisha

  公开号：US04751302A1

  公开（公告）日：1988-06-14

  A compound of the formula (I): ##STR1## wherein W.sub.1 and W.sub.2 each independently is a hydrogen atom or a ##STR2## wherein Y is a n-C.sub.1-6 alkylene group or a n-C.sub.1-6 alkylene group having a C.sub.1-6 alkyl group substituent; and R.sub.1 and R.sub.2 each independently is a hydrogen atom or a C.sub.1-6 alkyl group, and ##STR3## may form a saturated heterocyclic ring selected from the group consisting of morpholino, pyrrolidino, piperidino, homopiperidino and piperazino groups, and the saturated heterocyclic ring except the morpholino group may have at least one C.sub.1-4 alkyl group, hydroxyl group or halogen atom as a substituent; Z.sub.1 is a hydrogen atom, a chlorine atom, a bromine atom, an iodine atom, a hydroxyl group, an amino group, a C.sub.1-3 alkyl group or a methoxy group; Z.sub.2 is a hydrogen atom or an amino group; when W.sub.1 and W.sub.2 are both hydrogen atoms, Z.sub.1 is a hydroxyl group or an iodine atom and Z.sub.2 is hydrogen atom, or Z.sub.1 and Z.sub.2 are both amino groups; when Z.sub.1 and Z.sub.2 are both hydrogen atoms, the ##STR4## in either W.sub.1 or W.sub.2 is a morpholino group; when Z.sub.1 is a chlorine atom, a hydroxyl group, an iodine atom, a methyl group or a methoxy group, Z.sub.2 is a hydrogen atom; when Z.sub.1 is an amino group, Z.sub.2 is a hydrogen atom or an amino group; when Z.sub.1 is a methyl group, a methoxy group or an amino group, Z.sub.1 is in the 5-position; when Z.sub.1 is an iodine atom, Z.sub.1 is in the 5- or 7-position; and when Z.sub.1 and Z.sub.2 are both amino groups, Z.sub.1 and Z.sub.2 are in the 5- and 7-positions; and the physiologically acceptable acid addition salt thereof.

  化合物的公式（I）：##STR1## 其中W.sub.1和W.sub.2各自独立地是氢原子或##STR2##其中Y是n-C.sub.1-6烷基或具有C.sub.1-6烷基取代基的n-C.sub.1-6烷基；R.sub.1和R.sub.2各自独立地是氢原子或C.sub.1-6烷基，且##STR3##可以形成从吗啡啶，吡咯烷，哌啶，同哌啶和哌嗪基中选出的饱和杂环环，除吗啡啶基外的饱和杂环环可以具有至少一个C.sub.1-4烷基，羟基或卤原子作为取代基；Z.sub.1是氢原子，氯原子，溴原子，碘原子，羟基，氨基，C.sub.1-3烷基或甲氧基；Z.sub.2是氢原子或氨基；当W.sub.1和W.sub.2都是氢原子时，Z.sub.1是羟基或碘原子，Z.sub.2是氢原子，或者Z.sub.1和Z.sub.2都是氨基；当Z.sub.1和Z.sub.2都是氢原子时，W.sub.1或W.sub.2中的##STR4##是吗啡啶基；当Z.sub.1是氯原子，羟基，碘原子，甲基或甲氧基时，Z.sub.2是氢原子；当Z.sub.1是氨基时，Z.sub.2是氢原子或氨基；当Z.sub.1是甲基，甲氧基或氨基时，Z.sub.1在5位；当Z.sub.1是碘原子时，Z.sub.1在5位或7位；当Z.sub.1和Z.sub.2都是氨基时，Z.sub.1和Z.sub.2在5位和7位；以及其生理上可接受的酸加成盐。
• Aminoindazole derivatives
  申请人：Asahi Kasei Kogyo Kabushiki Kaisha

  公开号：US04533731A1

  公开（公告）日：1985-08-06

  A compound of the formula (I): ##STR1## wherein W.sub.1 and W.sub.2 each independently is a hydrogen atom or a ##STR2## group wherein Y is a n-C.sub.1-6 alkylene group or a n-C.sub.1-6 alkylene group having a C.sub.1-6 alkyl group substituent; and R.sub.1 and R.sub.2 each independently is a hydrogen atom or a C.sub.1-6 alkyl group, and ##STR3## group in ##STR4## group may form a saturated heterocyclic ring selected from the group consisting of morpholino, pyrrolidino, piperidino, homopiperidino and piperazino groups, and the saturated heterocyclic ring except the morpholino group may have at least one C.sub.1-4 alkyl group, hydroxyl group or halogen atom as a substituent; Z.sub.1 is a hydrogen atom, a chlorine atom, a bromine atom, an iodine atom, a hydroxyl group, an amino group, a C.sub.1-3 alkyl group or a methoxy group; Z.sub.2 is a hydrogen atom or an amino group; when W.sub.1 and W.sub.2 are both hydrogen atoms, Z.sub.1 is a hydroxyl group or an iodine atom and Z.sub.2 is hydrogen atom, or Z.sub.1 and Z.sub.2 are both amino groups; when Z.sub.1 and Z.sub.2 are both hydrogen atoms, the ##STR5## group in either W.sub.1 or W.sub.2 is a morpholino group; when Z.sub.1 is a chlorine atom, a hydroxyl group, an iodine atom, a methyl group or a methoxy group, Z.sub.2 is a hydrogen atom; when Z.sub.1 is an amino group, Z.sub.2 is a hydrogen atom or an amino group; when Z.sub.1 is a methyl group, a methoxy group or an amino group, Z.sub.1 is in the 5-position; when Z.sub.1 is an iodine atom, Z.sub.1 is in the 5- or 7-position; and when Z.sub.1 and Z.sub.2 are both amino groups, Z.sub.1 and Z.sub.2 are in the 5- and 7-positions; and the physiologically acceptable acid addition salt thereof which compounds have pharmaceutical utility, e.g.: treating inflammation.

  化合物的式子（I）：##STR1## 其中W.sub.1和W.sub.2各自独立地是氢原子或##STR2##基团，其中Y是n-C.sub.1-6烷基或具有C.sub.1-6烷基取代基的n-C.sub.1-6烷基；R.sub.1和R.sub.2各自独立地是氢原子或C.sub.1-6烷基，并且##STR3##在##STR4##基团中可以形成选择自吗啡啶，吡咯烷，哌啶，同哌啶和哌嗪基团的饱和杂环环，除了吗啡啶基团的饱和杂环环可以具有至少一个C.sub.1-4烷基，羟基或卤素原子作为取代基；Z.sub.1是氢原子，氯原子，溴原子，碘原子，羟基，氨基，C.sub.1-3烷基或甲氧基；Z.sub.2是氢原子或氨基；当W.sub.1和W.sub.2都是氢原子时，Z.sub.1是羟基或碘原子，Z.sub.2是氢原子，或者Z.sub.1和Z.sub.2都是氨基；当Z.sub.1和Z.sub.2都是氢原子时，W.sub.1或W.sub.2中的##STR5##基团是吗啡啶基团；当Z.sub.1是氯原子，羟基，碘原子，甲基或甲氧基时，Z.sub.2是氢原子；当Z.sub.1是氨基时，Z.sub.2是氢原子或氨基；当Z.sub.1是甲基，甲氧基或氨基时，Z.sub.1在5位；当Z.sub.1是碘原子时，Z.sub.1在5-或7-位置；当Z.sub.1和Z.sub.2都是氨基时，Z.sub.1和Z.sub.2在5-和7-位置；以及其生理上可接受的酸加成盐，这些化合物具有药用价值，例如：用于治疗炎症。
• 3-aminoindazole derivatives
  申请人：Asahi Kasei Kogyo Kabushiki Kaisha

  公开号：US04585869A1

  公开（公告）日：1986-04-29

  A compound of the formula (I): ##STR1## wherein W.sub.1 is a hydrogen atom or a ##STR2## wherein Y is a C.sub.1-6 alkylene group or a C.sub.1-6 alkylene group having a C.sub.1-6 alkyl group substituent; and R.sub.1 and R.sub.2 each independently is a hydrogen atom or a C.sub.1-6 alkyl group and R.sub.1 and R.sub.2 may form a C.sub.4-6 heterocyclic ring or a nitrogen-containing C.sub.4-6 heterocyclic ring together with the adjacent nitrogen atom and the C.sub.4-6 heterocyclic rings may have at least one C.sub.1-6 alkyl group, hydroxyl group or halogen atom; W.sub.2 is a hydrogen atom or a ##STR3## wherein Z is a C.sub.1-6 alkylene group or a C.sub.1-6 alkylene group having a C.sub.1-6 alkyl group substituent; and R.sub.3 and R.sub.4 each independently is a hydrogen atom or a C.sub.1-6 alkyl group and R.sub.3 and R.sub.4 may form a C.sub.4-6 heterocyclic ring or a nitrogen-containing C.sub.4-6 heterocyclic ring together with the adjacent nitrogen atom and the C.sub.4-6 heterocyclic rings may have at least one C.sub.1-6 alkyl group, hydroxyl group or halogen atom; when W.sub.1 is a hydrogen atom, W.sub.2 is the ##STR4## and when W.sub.2 is a hydrogen atom, W.sub.1 is the ##STR5## and the pharmaceutically acceptable acid addition salt thereof having antiinflammatory, analgesic and digestive tract ulcer suppressing activity.

  化合物的公式(I)：##STR1## 其中W.sub.1为氢原子或##STR2##其中Y是C.sub.1-6烷基或具有C.sub.1-6烷基取代基的C.sub.1-6烷基；R.sub.1和R.sub.2各自独立地为氢原子或C.sub.1-6烷基，且R.sub.1和R.sub.2可以与相邻氮原子一起形成C.sub.4-6杂环或含氮C.sub.4-6杂环，而C.sub.4-6杂环可以具有至少一个C.sub.1-6烷基，羟基或卤素原子；W.sub.2为氢原子或##STR3##其中Z是C.sub.1-6烷基或具有C.sub.1-6烷基取代基的C.sub.1-6烷基；R.sub.3和R.sub.4各自独立地为氢原子或C.sub.1-6烷基，且R.sub.3和R.sub.4可以与相邻氮原子一起形成C.sub.4-6杂环或含氮C.sub.4-6杂环，而C.sub.4-6杂环可以具有至少一个C.sub.1-6烷基，羟基或卤素原子；当W.sub.1为氢原子时，W.sub.2为##STR4##当W.sub.2为氢原子时，W.sub.1为##STR5##以及其药学上可以接受的酸加成盐，具有抗炎，镇痛和消化道溃疡抑制活性。
• 3-Aminoindazole derivatives and process for preparation thereof
  申请人：Asahi Kasei Kogyo Kabushiki Kaisha

  公开号：EP0049779A1

  公开（公告）日：1982-04-21

  A compound of the formula (I): wherein W, is a hydrogen atom or a group wherein Y is a C1-6 alkylene group or a C1-6 alkylene group having a C1-6 alkyl group substituent; and R, and R2 each independently is a hydrogen atom or a C1-6 alkyl group and R,, R2 and the adjacent nitrogen atom may form a C4-6 heterocyclic ring or a C4-6 heterocyclic ring containing an additional nitrogen atom and the C4-6 heterocyclic rings may have at least one C1-6 alkyl group, hydroxyl group or halogen atom; W2 is a hydrogen atom or a group wherein Z is a C1-6 alkylene group or a C1-6 alkylene group having a C1-6 alkyl group substituent; and R3 and R4 each independently is a hydrogen atom or a C1-6 alkyl group and R3, R4 and the adjacent nitrogen atom may form a C4-6 hetercyclic ring or a C4-6 heterocyclic ring containing an additional nitrogen atom and the C4-6 heterocyclic rings may have at least one C1-6 alkyl group, hydroxyl group or halogen atom; when W, is a hydrogen atom, W2 is the group; and when W2 is a hydrogen atom, W, is the group; and the pharmaceutically acceptable acid addition salt thereof.

  式 (I) 的化合物： 其中 W，是氢原子或 其中 Y 是 C1-6 亚烷基或具有 C1-6 烷基取代基的 C1-6 亚烷基；R 和 R2 各自独立地是氢原子或 C1-6 烷基，且 R、R2 和相邻的氮原子可形成 C4-6 杂环或含有额外氮原子的 C4-6 杂环，且 C4-6 杂环可具有至少一个 C1-6 烷基、羟基或卤素原子； W2 是氢原子或 其中 Z 为 C1-6 亚烷基或具有 C1-6 烷基取代基的 C1-6 亚烷基；以及 R3 和 R4 各自独立地为氢原子或 C1-6 烷基，且 R3、R4 和相邻氮原子可形成 C4-6 杂环或含有额外氮原子的 C4-6 杂环，且 C4-6 杂环可具有至少一个 C1-6 烷基、羟基或卤素原子； 当 W 是氢原子时，W2 是 基团；以及 当 W2 是氢原子时，W, 是基团；及 基团；及其药学上可接受的酸加成盐。